FREMONT, Calif., Oct. 22 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel RNA interference-based therapeutics, announced today that it is scheduled to present on Tuesday, November 6, 2007 at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference and the CIBC World Markets 18th Annual Healthcare Conference. Gavin Samuels, M.D., Senior Vice President of Business Development will be presenting.
About Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. is a development-stage pharmaceutical company engaged in discovering and developing novel therapeutic RNAi drug candidates. Quark has a fully integrated drug development platform that spans therapeutic target identification to drug development and includes:
Quark has a robust product portfolio including two clinical, one pre-IND and six preclinical candidates in development. Its lead product candidates are RTP801i-14, an siRNA molecule in phase I/IIa clinical trial for the treatment of wet age-related macular degeneration that is licensed to Pfizer on an exclusive worldwide basis, AKIi-5, an siRNA molecule for the prevention of acute kidney injury / acute renal failure, and AHLi-11, an siRNA molecule for the prevention of chemotherapy and noise-induced hearing loss.
Quark is headquartered in Fremont, California and operates research and development facilities in Boulder, Colorado and Ness-Ziona, Israel. Additional information is available at www.quarkpharma.com
GSamuels@quarkpharma.comscarrington@theruthgroup.comescott@theruthgroup.comjmccargo@theruthgroup.com
CONTACT: Gavin Samuels of Quark Pharmaceuticals, Inc., +1-510-449-6737,
GSamuels@quarkpharma.com; or Investors: Stephanie Carrington,
+1-646-536-7017, scarrington@theruthgroup.com, or Elizabeth Scott,
+1-646-536-7014, escott@theruthgroup.com; or Media: Janine McCargo,
+1-646-536-7033, jmccargo@theruthgroup.com, all of The Ruth Group
Web site: http://www.quarkpharma.com/
